|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ulisse S, Baldini E, Sorrenti S, Barollo
S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, et
al: In papillary thyroid carcinoma BRAFV600E is associated with
increased expression of the urokinase plasminogen activator and its
cognate receptor, but not with disease-free interval. Clin
Endocrinol. 77:780–786. 2012. View Article : Google Scholar
|
|
4
|
Benvenga S and Koch CA: Molecular pathways
associated with aggressiveness of papillary thyroid cancer. Curr
Genomics. 15:162–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu X, Bishop J, Shan Y, Pai S, Liu D,
Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent
TERT promoter mutations in aggressive thyroid cancers.
Endocr Relat Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carina V, Zito G, Pizzolanti G, Richiusa
P, Criscimanna A, Rodolico V, Tomasello L, Pitrone M, Arancio W and
Giordano C: Multiple pluripotent stem cell markers in human
anaplastic thyroid cancer: The putative upstream role of SOX2.
Thyroid. 23:829–837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yasui K, Shimamura M, Mitsutake N and
Nagayama Y: SNAIL induces epithelial-to-mesenchymal transition and
cancer stem cell-like properties in aldehyde
dehydroghenase-negative thyroid cancer cells. Thyroid. 23:989–996.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Landa I, Ibrahimpasic T, Boucai L, Sinha
R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP,
Xu B, et al: Genomic and transcriptomic hallmarks of poorly
differentiated and anaplastic thyroid cancers. J Clin Invest.
126:1052–1066. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dettmer MS, Perren A, Moch H, Komminoth P,
Nikiforov YE and Nikiforova MN: MicroRNA profile of poorly
differentiated thyroid carcinomas: New diagnostic and prognostic
insights. J Mol Endocrinol. 52:181–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pallante P, Battista S, Pierantoni GM and
Fusco A: Deregulation of microRNA expression in thyroid neoplasias.
Nat Rev Endocrinol. 10:88–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Damanakis AI, Eckhardt S, Wunderlich A,
Roth S, Wissniowski TT, Bartsch DK and Di Fazio P: MicroRNAs let7
expression in thyroid cancer: Correlation with their deputed
targets HMGA2 and SLC5A5. J Cancer Res Clin Oncol. 142:1213–1220.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Piovan C, Palmieri D, Di Leva G, Braccioli
L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi
T, et al: Oncosuppressive role of p53-induced miR-205 in triple
negative breast cancer. Mol Oncol. 6:458–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boll K, Reiche K, Kasack K, Mörbt N,
Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn
F, et al: MiR-130a, miR-203 and miR-205 jointly repress key
oncogenic pathways and are downregulated in prostate carcinoma.
Oncogene. 32:277–285. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang M, Zhang P, Hu G, Xiao Z, Xu F,
Zhong T, Huang F, Kuang H and Zhang W: Relative expressions of
miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of
non-small cell lung cancer patients. Mol Cell Biochem. 383:67–75.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Zhao X, Wang D, He W, Zhang S, Cao
W, Huang Y, Wang L, Zhou S and Luo K: Up-regulated expression of
phospholipase C, beta1 is associated with tumor cell proliferation
and poor prognosis in hepatocellular carcinoma. Onco Targets Ther.
9:1697–1706. 2016.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
ELife. 4:2015. View Article : Google Scholar
|
|
19
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rosenbluh J, Nijhawan D, Cox AG, Li X,
Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et
al: β-Catenin-driven cancers require a YAP1 transcriptional complex
for survival and tumorigenesis. Cell. 151:1457–1473. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang H, Chen B, Duan B, Zheng J and Wu X:
miR205 suppresses cell proliferation, invasion, and metastasis via
regulation of the PTEN/AKT pathway in renal cell carcinoma. Mol Med
Rep. 14:3343–3349. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lebanony D, Benjamin H, Gilad S, Ezagouri
M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, et
al: Diagnostic assay based on hsa-miR-205 expression distinguishes
squamous from nonsquamous non-small-cell lung carcinoma. J Clin
Oncol. 27:2030–2037. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Childs G, Fazzari M, Kung G, Kawachi N,
Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV,
Prystowsky MB, et al: Low-level expression of microRNAs let-7d and
miR-205 are prognostic markers of head and neck squamous cell
carcinoma. Am J Pathol. 174:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang T, Zhang J, Cui M, Liu F, You X, Du
Y, Gao Y, Zhang S, Lu Z, Ye L and Zhang X: Hepatitis B virus X
protein inhibits tumor suppressor miR-205 through inducing
hypermethylation of miR-205 promoter to enhance carcinogenesis.
Neoplasia. 15:1282–1291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gandellini P, Folini M, Longoni N, Pennati
M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta
P, et al: miR-205 Exerts tumor-suppressive functions in human
prostate through down-regulation of protein kinase Cepsilon. Cancer
Res. 69:2287–2295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bhatnagar N, Li X, Padi SK, Zhang Q, Tang
MS and Guo B: Downregulation of miR-205 and miR-31 confers
resistance to chemotherapy-induced apoptosis in prostate cancer
cells. Cell Death Dis. 1:e1052010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu Y, Qiu Y, Yague E, Ji W, Liu J and
Zhang J: miRNA-205 targets VEGFA and FGF2 and regulates resistance
to chemotherapeutics in breast cancer. Cell Death Dis. 7:e22912016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q
and Tao R: MicroRNA-205 functions as a tumor suppressor in human
glioblastoma cells by targeting VEGF-A. Oncol Rep. 27:1200–1206.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karaayvaz M, Zhang C, Liang S, Shroyer KR
and Ju J: Prognostic significance of miR-205 in endometrial cancer.
PLoS One. 7:e351582012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Quesne JL, Jones J, Warren J, Dawson SJ,
Ali HR, Bardwell H, Blows F, Pharoah P and Caldas C: Biological and
prognostic associations of miR-205 and let-7b in breast cancer
revealed by in situ hybridization analysis of micro-RNA expression
in arrays of archival tumour tissue. J Pathol. 227:306–314. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun X, Du P, Yuan W, Du Z, Yu M, Yu X and
Hu T: Long non-coding RNA HOTAIR regulates cyclin J via inhibition
of microRNA-205 expression in bladder cancer. Cell Death Dis.
6:e19072015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bora-Singhal N, Nguyen J, Schaal C,
Perumal D, Singh S, Coppola D and Chellappan S: YAP1 regulates OCT4
activity and SOX2 expression to facilitate self-renewal and
vascular mimicry of stem-like cells. Stem Cells. 33:1705–1718.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Song S, Honjo S, Jin J, Chang SS, Scott
AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et
al: The Hippo coactivator YAP1 mediates EGFR overexpression and
confers chemoresistance in esophageal cancer. Clin Cancer Res.
21:2580–2590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hudson J, Duncavage E, Tamburrino A,
Salerno P, Xi L, Raffeld M, Moley J and Chernock RD: Overexpression
of miR-10a and miR-375 and downregulation of YAP1 in medullary
thyroid carcinoma. Exp Mol Pathol. 95:62–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garcia-Rendueles ME, Ricarte-Filho JC,
Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS,
Persaud Y, et al: NF2 loss promotes oncogenic RAS-induced thyroid
cancers via YAP-dependent transactivation of RAS proteins and
sensitizes them to MEK inhibition. Cancer Discov. 5:1178–1193.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kang W, Tong JH, Lung RW, Dong Y, Zhao J,
Liang Q, Zhang L, Pan Y, Yang W, Pang JC, et al: Targeting of YAP1
by microRNA-15a and microRNA-16-1 exerts tumor suppressor function
in gastric adenocarcinoma. Mol Cancer. 14:522015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lei CJ, Li L, Gao X, Zhang J, Pan QY, Long
HC, Chen CZ, Ren DF and Zheng G: Hsa-miR-132 inhibits proliferation
of hepatic carcinoma cells by targeting YAP. Cell Biochem Funct.
33:326–333. 2015. View
Article : Google Scholar : PubMed/NCBI
|
